W. L. Gore & Associates (Gore) today reported the first Australian patients enrolled in the Global Registry for Endovascular Aortic Treatment (GREAT). The Registry is part of Gore's dedication to post-market surveillance, monitoring patient and device performance in an effort to improve clinical practice, and patient outcomes. Devices studied in the Registry include the GORE® TAG® Thoracic Endoprosthesis, GORE® EXCLUDER® AAA Endoprosthesis, and GORE® EXCLUDER® AAA Endoprosthesis featuring C3 Delivery System.
“On-going clinical research and partnership with clinicians will help Gore and physicians continue to improve patient care.”
Vascular surgeons at Royal Prince Alfred Hospital in Camperdown were the first in Australia to enroll patients in GREAT, following successful treatment for thoracic and abdominal aneurysms. Steven Dubenec, MD, Head of Department of Vascular Surgery and Michael Stephen, MD, performed the procedures.
"Australia and New Zealand have had an international presence as leaders in the development and advancement of aortic endovascular procedures since their inception. I believe GREAT will be a pivotal registry that may advance aortic endovascular therapies in the future," said Dr. Dubenec, National Principal Investigator for GREAT in Australia and New Zealand. "Our regional participation in this registry demonstrates the commitment of Australian and New Zealand vascular interventionalists to ongoing advancements in patient care in this field. Our patients can be assured that they are continuing to be offered the optimal technologically advanced, proven, and safe therapies for the treatment of aortic disease."
GREAT monitors outcomes during patient treatment and post-treatment visits for up to 10 years, providing longer-term follow-up than has been collected in past prospective registries. Active tracking of long-term device performance and associated patient outcomes will provide additional details regarding global trends in device usage, offering insights into clinical needs that may advance future aortic endovascular therapies. Patients are enrolled in GREAT once a procedure using a Gore endovascular minimally invasive device has been completed. Since August 2010, the registry has enrolled 274 patients in 15 sites globally.
"Gore is dedicated to advancing endovascular therapy and minimally invasive treatment options for patients worldwide," said Ryan Takeuchi, Gore Aortic Business Leader. "On-going clinical research and partnership with clinicians will help Gore and physicians continue to improve patient care."
Expanding research and clinical options for children with cancer